Fortress Biotech (NASDAQ:FBIO) CEO Buys $104,074.40 in Stock

Fortress Biotech logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • CEO Lindsay Rosenwald bought 54,776 shares for $104,074.40 at an average price of $1.90, increasing his holdings by 1.18% to 4,706,108 shares.
  • Fortress Biotech shares fell 5.7% to $1.78 on Thursday. Its latest quarterly loss of $0.23 per share was narrower than analysts expected, while revenue of $19.16 million fell short of forecasts.
  • Analysts’ consensus rating is Hold, with a stated average price target of $17.00; recent rating changes included downgrades from Weiss Ratings and Wall Street Zen.
  • MarketBeat previews top five stocks to own in December.

Fortress Biotech, Inc. (NASDAQ:FBIO - Get Free Report) CEO Lindsay Md Rosenwald acquired 54,776 shares of Fortress Biotech stock in a transaction on Wednesday, November 18th. The stock was acquired at an average cost of $1.90 per share, for a total transaction of $104,074.40. Following the purchase, the chief executive officer owned 4,706,108 shares of the company's stock, valued at approximately $8,941,605.20. This represents a 1.18% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Fortress Biotech Trading Down 5.7%

FBIO stock traded down $0.11 during trading on Thursday, hitting $1.78. The company had a trading volume of 194,841 shares, compared to its average volume of 586,980. The firm has a 50-day moving average price of $2.08 and a 200-day moving average price of $2.70. Fortress Biotech, Inc. has a 12 month low of $1.64 and a 12 month high of $4.53. The company has a quick ratio of 3.83, a current ratio of 2.93 and a debt-to-equity ratio of 0.10. The stock has a market cap of $60.16 million, a price-to-earnings ratio of 0.78 and a beta of 1.27.

Fortress Biotech (NASDAQ:FBIO - Get Free Report) last issued its earnings results on Friday, November 13th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.27) by $0.04. The firm had revenue of $19.16 million for the quarter, compared to analysts' expectations of $21.57 million. Fortress Biotech had a return on equity of 61.84% and a net margin of 143.04%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Weiss Ratings lowered Fortress Biotech from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Friday, October 23rd. Wall Street Zen lowered Fortress Biotech from a "strong-buy" rating to a "hold" rating in a research note on Saturday, August 15th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $17.00.

View Our Latest Analysis on Fortress Biotech

Institutional Investors Weigh In On Fortress Biotech

Large investors have recently added to or reduced their stakes in the company. Marshall Wace LLP purchased a new stake in Fortress Biotech in the third quarter worth about $462,000. Squarepoint Ops LLC purchased a new stake in Fortress Biotech in the 2nd quarter worth approximately $47,000. Finally, Renaissance Technologies LLC raised its stake in Fortress Biotech by 22.8% during the 1st quarter. Renaissance Technologies LLC now owns 99,590 shares of the biopharmaceutical company's stock worth $278,000 after acquiring an additional 18,490 shares during the period. Institutional investors own 96.51% of the company's stock.

More Fortress Biotech News

Here's some of the latest news about FBIO:

  • Positive Sentiment: CEO Lindsay Rosenwald bought 136,723 shares across three transactions from November 17–19, spending about $253,000. CFO David Jin also bought 47,605 shares over the same period for approximately $88,000. These open-market purchases increased both executives’ holdings and may signal confidence in the company. CEO SEC filing CFO SEC filing
  • Neutral Sentiment: HC Wainwright forecast EPS of $2.66 for FY2026 and $2.37 for FY2027. The report also estimated a Q4 2026 loss of $0.15 per share; the articles did not provide a rating change or explain the basis for the annual forecasts. Analyst insights article

About Fortress Biotech

(Get Free Report)

Fortress Biotech, Inc. is a biopharmaceutical company that develops and commercializes prescription medicines through a network of subsidiaries and affiliated companies. Its approach includes advancing drug candidates, acquiring or licensing development and commercialization rights, and building companies around selected products and programs. The company's activities span areas including oncology, dermatology, rare diseases and immunology. Its portfolio has included marketed dermatology medicines such as Qbrexza, Amzeeq and Zilxi, as well as investigational therapies at various stages of development.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Fortress Biotech Right Now?

Before you consider Fortress Biotech, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fortress Biotech wasn't on the list.

While Fortress Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines